CompletedEUCTR 2010-020008-31

A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease

This historical record does not confirm current site availability.

Historical research recordUnited KingdomSchizophrenia

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: United Kingdom
Study phase: Phase 2

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: Not clearly listed
Sponsor: ACADIA Pharmaceuticals Inc
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United Kingdom
Age range: Not clearly listed
Official registry ID: EUCTR 2010-020008-31
Official title: Show the full official title
A Single center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer’s Disease

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

United Kingdom

Registry details

Historical country statuses

United Kingdom — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is ACADIA Pharmaceuticals Inc.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me